Clinical evaluation of phytomedicines used at Alango Foundation in the treatment of Rubella, Toxoplasmosis, Syphilis and Chlamydiosis

This work is essentially focused on the clinical evaluation of phytomedicines used at the Alango Foundation in the treatment of infectious diseases. During our study period (July 2018 to February 2019), the powder from the bark of the plants was administered to patients seen in consultation at the Alango Foundation. Our interest in these plants is based on their effectiveness in the treatment of rubella, Toxoplasmosis, Syphilis, and Chlamydia in the clinic of African medicine. During this period, based on the results of the biomedical analysis, and the positive evolution of the symptoms, we observed the recovery of the patients. According to the epidemiological statistical results, we recorded 222 patients cured of Rubella out of 290 infected patients, a percentage of 76.55%; 113 patients cured of Toxoplasmosis out of 141 infected patients, ie a percentage of 80.14%; 32 patients cured of Chlamydia out of 34 infected patients, ie a percentage of 94.11%; 07 patients cured of Syphilis out of 10 infected patients, ie a percentage of 70%. The phytomedicines that were responsible for the cure were: ECANDOL™ (Entandrophragma candollei), DANIOLI ™ (Daniella oliveri), GONDINE ™ (Lannea barteri), IROBA ™ (Milicia excelsa), ECHAMOU ™ (Erythrina senegalensis), CLAMINE™ (Entandrophragma utile, BATUS ™ (Lophira lanceolata). of all these phytomedicines, ECANDOL ™ is the phytomedicine that completed Phase 3 of the clinical evaluation for the treatment of Rubella, which is why we have considered it as a Standardized Phytomedicine. The other phytomedicines such as DANIOLI ™, GONDINE ™, IROBA ™, ECHAMOU ™, CLAMINE ™ have completed phase 2 of the clinical evaluation, which is why they are considered to be phytomedicines in the process of standardization.
Keywords: Clinical evaluation, Phytomedicines, Standardization, monographs, infectious diseases